Emergence of Biosimilars in Oncology

Emergence of Biosimilars in Oncology

Episodes

Specialty:

All

Year:

All

EP. 1: An Overview of Biosimilarity

March 16th 2020

EP. 2: The Adoption and Choice of Biosimilars

March 16th 2020

EP. 3: Decision Makers for Formulary Approval of Biosimilars

March 16th 2020

EP. 4: Biosimilar Use in the Treatment of NSCLC

March 16th 2020

EP. 5: The Use of Biosimilars in HER2+ Breast Cancer

March 16th 2020

EP. 6: The Complexity of Choosing Biosimilars in Oncology

March 16th 2020

EP. 7: Evidence-Based Extrapolation for Biosimilars

March 16th 2020

EP. 8: Biosimilar Interchangeability in Practice

March 16th 2020

EP. 9: Pharmacovigilance Requirements for Biosimilar Products

March 16th 2020

EP. 10: Educating Physicians When Prescribing Biosimilars

March 16th 2020

EP. 11: The Availability of Multiple Biosimilars for 1 Biologic

March 16th 2020

EP. 12: The Future Direction of Biosimilars

March 16th 2020

Trending on OncLive

FDA Approves Imlunestrant Plus Abemaciclib for ER+, HER2–, ESR1-Mutated Metastatic Breast Cancer

EU Approval Reccomended by CHMP for Senaparib in First-Line Advanced Ovarian Cancer

CHMP Backs Perioperative Pembrolizumab Plus Enfortumab Vedotin for Resectable MIBC

CHMP Recommends Adjuvant T-DXd for HER2+ Early Breast Cancer With Residual Invasive Disease

Dr Gilbert on the Efficacy of Relacorilant Plus Nab-Paclitaxel in Ovarian Cancer